Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 1.00 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.54 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16651272 | 1.00 | BRD4 (1.00) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL16651456 | 0.78 | BRD4 (1.00) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL29849051 | 0.78 | BRD4 (1.00) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL16650475 | 0.75 | BRD4 (1.00) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL29848915 | 0.75 | BRD4 (1.00) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL5486071 | 0.73 | HTR2C (0.66) | BRD4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4345829 | 0.73 | BRD4 (0.57) | BRD4L3MBTL1 | |
| SCHEMBL29848807 | 0.72 | BRD4 (1.00) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL16651178 | 0.72 | BRD4 (1.00) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL13587950 | 0.72 | BRD4 (0.56) | BRD4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRD9 19/4885BRD7 14/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885BRD9 19/4885BRD7 14/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885BRD9 19/4885BRD7 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.